Metabolic issues and cardiovascular disease in patients with psychiatric disorders.
暂无分享,去创建一个
[1] M. Heo,et al. The distribution of body mass index among individuals with and without schizophrenia. , 1999, The Journal of clinical psychiatry.
[2] Jukka T Salonen,et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.
[3] E. Trinka,et al. Polycystic ovaries, obesity and insulin resistance in women with epilepsy , 2002, Journal of Neurology.
[4] D. Wirshing. Adverse effects of atypical antipsychotics. , 2001, The Journal of clinical psychiatry.
[5] T. Schwartz,et al. Psychiatric medication induced obesity: an aetiologic review , 2004, Obesity reviews : an official journal of the International Association for the Study of Obesity.
[6] G. L’italien,et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. , 2002, Archives of general psychiatry.
[7] B. Carroll,et al. Vascular risk factors in late onset mania , 2002, Psychological Medicine.
[8] P. Allebeck,et al. Schizophrenia: a life-shortening disease. , 1989, Schizophrenia bulletin.
[9] M. Lean,et al. Patients on Atypical Antipsychotic Drugs: Another high-risk group for type 2 diabetes , 2003 .
[10] P. Sparén,et al. Mortality and causes of death in schizophrenia in Stockholm County, Sweden , 2000, Schizophrenia Research.
[11] G. L’italien,et al. Weight gain and new onset diabetes associated with olanzapine and risperidone , 2004, Journal of General Internal Medicine.
[12] H. Nasrallah,et al. Medical Illness and Schizophrenia , 2003 .
[13] A. Goudie,et al. Antipsychotic‐induced weight gain , 2005, Diabetes, obesity & metabolism.
[14] Jennifer L. Greif,et al. Preventive health behaviors, health-risk behaviors, physical morbidity, and health-related role functioning impairment in veterans with post-traumatic stress disorder. , 2004, Military medicine.
[15] F. Charatan,et al. The effect of chlorpromazine (largactil) on glucose tolerance. , 1955, The Journal of mental science.
[16] S. Haffner,et al. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. , 2003, Diabetes care.
[17] S. Marder,et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials , 2003, Schizophrenia Research.
[18] J. Racoosin,et al. Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. , 2004, Diabetes care.
[19] W. Dietz,et al. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. , 2002, JAMA.
[20] T. Baptista. Body weight gain induced by antipsychotic drugs: mechanisms and management , 1999, Acta psychiatrica Scandinavica.
[21] S. Marder,et al. The effects of novel antipsychotics on glucose and lipid levels. , 2002, The Journal of clinical psychiatry.
[22] H. Yoshimatsu,et al. Hypothalamic neuronal histamine: implications of its homeostatic control of energy metabolism. , 1997, Nutrition.
[23] H. Stassen,et al. Mortality of patients with mood disorders: follow-up over 34-38 years. , 2002, Journal of affective disorders.
[24] J. Raniwalla,et al. Weight changes in patients treated with seroquel (quetiapine) , 2000, Schizophrenia Research.
[25] Julie Kreyenbuhl,et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study , 2002, BMJ : British Medical Journal.
[26] Robert F. Reynolds,et al. Serious Cardiovascular Events and Mortality Among Patients with Schizophrenia , 2004, The Journal of nervous and mental disease.
[27] C. Nemeroff,et al. Dosing the antipsychotic medication olanzapine. , 1997, The Journal of clinical psychiatry.
[28] S. Davidson,et al. Cardiovascular Risk Factors for People with Mental Illness , 2001, The Australian and New Zealand journal of psychiatry.
[29] Anne W. Schmidt,et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. , 1995, The Journal of pharmacology and experimental therapeutics.
[30] R. Bland,et al. Mortality in a Cohort of Patients with Schizophrenia: A Record Linkage Study* , 1991, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[31] P. Macfarlane,et al. Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study , 2003, Circulation.
[32] J. Birtwistle,et al. The unhealthy lifestyle of people with schizophrenia , 1999, Psychological Medicine.
[33] J. Thakore,et al. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. , 2002, Life sciences.
[34] D. Dwyer,et al. Antipsychotic drugs affect glucose uptake and the expression of glucose transporters in PC12 cells , 1999, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[35] J. Csernansky,et al. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. , 2002, The New England journal of medicine.
[36] B. Harvey,et al. Neuropharmacology of Paradoxic Weight Gain with Selective Serotonin Reuptake Inhibitors , 2000, Clinical neuropharmacology.
[37] T. Valle,et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.
[38] T. Stern,et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. , 1999, Psychosomatics.
[39] R. Mcquade,et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. , 2004, The Journal of clinical psychiatry.
[40] L. Niskanen,et al. Metabolic syndrome in patients with schizophrenia. , 2003, The Journal of clinical psychiatry.
[41] J. Thakore,et al. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. , 2004, Life sciences.
[42] A. Sherwood,et al. Depression as a Risk Factor for Coronary Artery Disease: Evidence, Mechanisms, and Treatment , 2004, Psychosomatic medicine.
[43] E. Yano,et al. Use of general medical services by VA patients with psychiatric disorders. , 2002, Psychiatric services.
[44] J. Newcomer,et al. Atypical Antipsychotics and Metabolic Dysregulation: Evaluating the Risk/Benefit Equation and Improving the Standard of Care , 2004, Journal of clinical psychopharmacology.
[45] D. Daniel,et al. Effect of Divalproex Combined with Olanzapine or Risperidone in Patients with an Acute Exacerbation of Schizophrenia , 2003, Neuropsychopharmacology.
[46] S. Zorn,et al. The pharmacology of weight gain with antipsychotics. , 2001, The Journal of clinical psychiatry.
[47] A. Astrup,et al. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. , 1992, Metabolism: clinical and experimental.
[48] P. Bech,et al. LITHIUM TREATMENT AND WEIGHT GAIN , 1976, Acta psychiatrica Scandinavica.
[49] P. Sparén,et al. Excess mortality in bipolar and unipolar disorder in Sweden. , 2001, Archives of general psychiatry.
[50] S. Kennedy,et al. Valproate, bipolar disorder and polycystic ovarian syndrome. , 2003, Bipolar disorders.
[51] E. Gibson,et al. Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability. , 1997, Trends in pharmacological sciences.
[52] L. Dixon,et al. Prevalence and correlates of diabetes in national schizophrenia samples. , 2000, Schizophrenia bulletin.
[53] B. Barraclough,et al. Excess mortality of mental disorder , 1998, British Journal of Psychiatry.
[54] B. Harvey,et al. Phasic craving for carbohydrate observed with citalopram , 1996, International clinical psychopharmacology.
[55] M. Carnethon,et al. Symptoms of depression as a risk factor for incident diabetes: findings from the National Health and Nutrition Examination Epidemiologic Follow-up Study, 1971-1992. , 2003, American journal of epidemiology.
[56] Jonathan M. Meyer. Novel antipsychotics and severe hyperlipidemia. , 2001 .
[57] M. Heo,et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. , 1999, The American journal of psychiatry.
[58] M. Tsuang,et al. Causes of Death in Schizophrenia and Manic-Depression , 1980, British Journal of Psychiatry.
[59] J. Vázquez-Barquero,et al. Determinants of smoking behaviour in outpatients with schizophrenia , 2000, Schizophrenia Research.
[60] Anthony Gamst,et al. Association of the Metabolic Syndrome With History of Myocardial Infarction and Stroke in the Third National Health and Nutrition Examination Survey , 2004, Circulation.